Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,545,884

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,545,884 protect, and when does it expire?

Patent 8,545,884 protects GILOTRIF and is included in one NDA.

This patent has thirty-nine patent family members in thirty-five countries.

Summary for Patent: 8,545,884
Title:Solid pharmaceutical formulations comprising BIBW 2992
Abstract: The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA.sub.2) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA.sub.2, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.
Inventor(s): Messerschmid; Roman (Biberach, DE), Friedl; Thomas (Ochsenhausen, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/995,715
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,545,884
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,545,884

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-001 Jul 12, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-002 Jul 12, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-003 Jul 12, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,545,884

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08157800Jun 6, 2008
09160297May 14, 2009
PCT Information
PCT FiledJune 05, 2009PCT Application Number:PCT/EP2009/056944
PCT Publication Date:December 10, 2009PCT Publication Number: WO2009/147238

International Family Members for US Patent 8,545,884

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072062   Start Trial
Australia 2009254574   Start Trial
Brazil PI0913379   Start Trial
Canada 2726472   Start Trial
Chile 2010001275   Start Trial
China 102056589   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.